Hyperphosphatemia
Conditions
Interventions
Part A: Oral single administration of triazolam 0.25 mg at single administration phase, followed by an oral single administration of triazolam 0.25 mg and TS-172 20 mg at concomitant administration ph
Sponsors
Seiji Development Mita
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1. Japanese healthy adult males whose age is >=18 and =18.5 and <25.0 at the screening test 3. Subjects who are judged by a principal investigator or a sub-investigator to be eligible for participation in the study based on the results at the screening test and before administration of the drugs used in the study 4. Subjects who have been informed of the clinical trial, understand the details of the trial, and give their written consent prior to participation in the trial
Exclusion criteria
Exclusion criteria: 1. Subjects with medical history ineligible for participation in the study such as of respiratory, cardiovascular, gastrointestinal, hepatic, renal, urologic, endocrine, metabolic, hematologic, immunologic, dermatologic, neurologic, or psychiatric diseases 2. Subjects with medical history of disease (e.g., stomach or intestinal ulcers) or surgery (e.g., gastrectomy, gastric bandage, gastric bypass) that may affect the absorption of the drugs used in the study 3. Subjects who have been hospitalized with any treatment or undergone surgery within 12 weeks prior to receiving the drugs used in the study 4. Subjects with medical history of drug allergies (limited to severe symptoms such as anaphylaxis) or significant allergic predispositions (e.g., asthma that requires treatment) 5. Subjects who have used medications (including over-the-counter drugs) within 2 weeks prior to receiving the drugs used in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Drug concentration in plasma | — |
Contacts
Public ContactDevelopment Headquarters Management Development
Taisho Pharmaceutical Co., LTD.
Outcome results
None listed